Gastrointestinal cancer precursor risk and mortality in pancreatic intraductal papillary mucinous neoplasms : a nationwide cohort study
BACKGROUND AND AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a precursor of pancreatic cancer. While earlier research has shown a high prevalence of synchronous/metachronous extrapancreatic tumors in IPMN patients, these studies have often been small with retrospective data collection. The aim of the study was to examine absolute and relative risks of non-pancreatic gastrointestinal (GI) cancer precursors and mortality in histologically confirmed IPMN.
METHODS: Through the nationwide ESPRESSO histopathology cohort, we retrieved data on IPMN between 1965 and 2016. Each index case was matched to ≤5 general population controls. Through Cox regression, we estimated hazard ratios (HRs) for future GI cancer precursors and death.
RESULTS: A total of 117 patients with IPMN and 539 age- and sex-matched controls were included. Over a median of 2.1 years of follow up, we confirmed two (1.7%) incident GI cancer precursors in IPMN vs. four (0.7%) in controls, corresponding to an HR of 1.89 (95%CI = 0.34-10.55). By contrast, IPMN patients were at increased risk of death (HR 3.61 (95%CI = 1.79-7.27)). The most common cause of death in IPMN was pancreatic cancer (n = 14; 45.2% of all deaths).
CONCLUSIONS: We found no association between IPMN and other GI cancer precursors. This argues against comprehensive routine surveillance for other GI cancer precursors in IPMN patients. Mortality was increased in IPMN with pancreatic cancer being the most common cause of death, indicating the need for lifelong follow up in all resected and non-resected patients with IPMN. However, results should be confirmed in larger cohorts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Scandinavian journal of gastroenterology - 59(2024), 5 vom: 23. Apr., Seite 600-607 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vujasinovic, Miroslav [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/00365521.2024.2310162 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368417603 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368417603 | ||
| 003 | DE-627 | ||
| 005 | 20240426233710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/00365521.2024.2310162 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM368417603 | ||
| 035 | |a (NLM)38351653 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vujasinovic, Miroslav |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gastrointestinal cancer precursor risk and mortality in pancreatic intraductal papillary mucinous neoplasms |b a nationwide cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND AND AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a precursor of pancreatic cancer. While earlier research has shown a high prevalence of synchronous/metachronous extrapancreatic tumors in IPMN patients, these studies have often been small with retrospective data collection. The aim of the study was to examine absolute and relative risks of non-pancreatic gastrointestinal (GI) cancer precursors and mortality in histologically confirmed IPMN | ||
| 520 | |a METHODS: Through the nationwide ESPRESSO histopathology cohort, we retrieved data on IPMN between 1965 and 2016. Each index case was matched to ≤5 general population controls. Through Cox regression, we estimated hazard ratios (HRs) for future GI cancer precursors and death | ||
| 520 | |a RESULTS: A total of 117 patients with IPMN and 539 age- and sex-matched controls were included. Over a median of 2.1 years of follow up, we confirmed two (1.7%) incident GI cancer precursors in IPMN vs. four (0.7%) in controls, corresponding to an HR of 1.89 (95%CI = 0.34-10.55). By contrast, IPMN patients were at increased risk of death (HR 3.61 (95%CI = 1.79-7.27)). The most common cause of death in IPMN was pancreatic cancer (n = 14; 45.2% of all deaths) | ||
| 520 | |a CONCLUSIONS: We found no association between IPMN and other GI cancer precursors. This argues against comprehensive routine surveillance for other GI cancer precursors in IPMN patients. Mortality was increased in IPMN with pancreatic cancer being the most common cause of death, indicating the need for lifelong follow up in all resected and non-resected patients with IPMN. However, results should be confirmed in larger cohorts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Barrett | |
| 650 | 4 | |a IPMN | |
| 650 | 4 | |a adenoma | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a gastrointestinal | |
| 700 | 1 | |a Elbe, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Ekheden, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qiao-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Thuresson, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Roelstraete, Bjorn |e verfasserin |4 aut | |
| 700 | 1 | |a Ghazi, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Löhr, J-Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Ludvigsson, Jonas F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scandinavian journal of gastroenterology |d 1966 |g 59(2024), 5 vom: 23. Apr., Seite 600-607 |w (DE-627)NLM000055166 |x 1502-7708 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:5 |g day:23 |g month:04 |g pages:600-607 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/00365521.2024.2310162 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |e 5 |b 23 |c 04 |h 600-607 | ||